- Market Radar
- /
- VRTX
Sagehood
Financial Analyst
PREMIUM
Technical Trader
PREMIUM
Valuation Projection
PREMIUM
Social Media Buzz
PREMIUM
News Agent
PREMIUM
Macro Economist
PREMIUM
About VRTX
8/1/2025
Comprehensive Analysis
Financial Health
- Liquidity & Solvency: Vertex Pharmaceuticals maintains a current ratio of 2.69 and quick ratio of 2.20, reflecting robust short-term liquidity. Debt-to-equity is minimal at 0.007, with interest coverage well above breakeven, underscoring a conservative capital structure.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
- View 5 tickers daily
- Create and manage Watchlists
- Import portfolios (no personalized insights)
- Chat with the general Sagehood AI Agent
- Market Radar: Preview access only
Premium Membership
- Unlimited AI-generated insights across all sections
- Market Overview
- Market Radar (AI-driven investment opportunities)
- Access to all Sagehood AI agents, including domain-specific experts
- Personalized insights and actionable recommendations for smarter investing